PRALIDOXIME CHLORIDE (AUTOINJECTOR) Drug Patent Profile

When do Pralidoxime Chloride (autoinjector) patents expire, and when can generic versions of Pralidoxime Chloride (autoinjector) launch?

Pralidoxime Chloride (autoinjector) is a drug marketed by Meridian Medcl Techn and is included in one NDA.

The generic ingredient in PRALIDOXIME CHLORIDE (AUTOINJECTOR) is pralidoxime chloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pralidoxime chloride profile page.

Summary for PRALIDOXIME CHLORIDE (AUTOINJECTOR)

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	PRALIDOXIME CHLORIDE (AUTOINJECTOR) at DailyMed

US Patents and Regulatory Information for PRALIDOXIME CHLORIDE (AUTOINJECTOR)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Meridian Medcl Techn	PRALIDOXIME CHLORIDE (AUTOINJECTOR)	pralidoxime chloride	SOLUTION;INTRAMUSCULAR	018986-001	Apr 26, 1983		DISCN	Yes	No

Pralidoxime Chloride Autoinjector Market Dynamics and Financial Trajectory

Last updated: August 6, 2026

Pralidoxime chloride autoinjectors are niche emergency products with demand driven primarily by military procurement, government stockpiles, first-responder programs, and chemical-threat preparedness. The U.S. market is strategically important but commercially small, with revenue concentrated in periodic government contracts rather than recurring retail prescriptions. Public companies do not generally disclose pralidoxime-autoinjector revenue as a separate line item, so the financial trajectory is best assessed through procurement cycles, product availability, manufacturing capacity, and competitive access.

What is pralidoxime chloride autoinjector used for?

Pralidoxime chloride, also known as 2-PAM chloride, is an oxime used with atropine to treat poisoning caused by organophosphorus nerve agents and organophosphate pesticides. It reactivates acetylcholinesterase before the enzyme becomes irreversibly inhibited. Atropine controls muscarinic effects, while pralidoxime addresses neuromuscular toxicity.[1]

The autoinjector format combines rapid administration with simplified field use. The principal U.S. product configuration contains:

Product characteristic	Typical specification
Active ingredients	Atropine sulfate and pralidoxime chloride
Pralidoxime dose	600 mg
Atropine dose	2.1 mg
Administration	Intramuscular
Primary users	Military personnel, first responders, emergency stockpiles
Principal indication	Organophosphorus nerve-agent or pesticide poisoning
Prescription status	Prescription-only emergency product

The autoinjector is generally used as part of a treatment protocol requiring repeat dosing, respiratory support, seizure control and hospital care. It is not a chronic-use pharmaceutical.

Which pralidoxime chloride autoinjector products are marketed?

The principal U.S. commercial products are DuoDote and ATNAA, both combination autoinjectors containing atropine and pralidoxime chloride.

Product	Active ingredients	Form	Primary market position
DuoDote	Atropine sulfate 2.1 mg and pralidoxime chloride 600 mg	Single-use IM autoinjector	Civilian emergency preparedness and government procurement
ATNAA	Atropine sulfate 2.1 mg and pralidoxime chloride 600 mg	Single-use IM autoinjector	Military and federal preparedness procurement
Pralidoxime chloride injection	Pralidoxime chloride, generally supplied in vials	Injectable solution or powder for reconstitution	Hospital, military and institutional use

DuoDote is associated with Meridian Medical Technologies, a Pfizer company. ATNAA is also associated with Meridian’s autoinjector manufacturing and government supply activities. The products compete less through retail prescribing than through qualification, supply reliability, regulatory status, contract history and the ability to meet surge requirements.

Generic pralidoxime injection is a competitive substitute in hospitals but does not provide the same field-use profile. Vials and reconstitution systems have lower unit complexity but require trained personnel, sterile handling and additional administration steps.

How large is the pralidoxime autoinjector market?

The addressable market is small relative to conventional pharmaceutical categories. Demand is determined by:

1. Government stockpile replenishment.
2. Military deployment requirements.
3. Civilian first-responder contracts.
4. Chemical-incident preparedness.
5. Product replacement caused by expiration or shelf-life limits.
6. Regulatory and clinical preference for rapid, combined administration.

The market has a high strategic value-to-volume ratio. A single national procurement can materially affect annual supplier revenue, while a delayed contract can create a sharp year-over-year decline.

Retail demand is limited because the product is not used routinely. Hospitals may maintain pralidoxime injection, but many do not purchase large quantities of autoinjectors unless they participate in a formal emergency-preparedness program.

What drives demand for pralidoxime autoinjectors?

Government stockpiling

U.S. federal and state agencies maintain medical countermeasure inventories for chemical, biological, radiological and nuclear threats. The Strategic National Stockpile and the Department of Defense are important demand centers for antidotes and autoinjectors.[2][3]

Stockpile purchasing creates a replacement market rather than a consumption market. Units are bought in advance, stored and replaced as they approach expiration. This produces episodic orders that can exceed normal commercial demand.

Military procurement

Military requirements support baseline demand because nerve-agent exposure is treated as a force-protection risk. Military buyers place a premium on:

• Field portability.
• One-step or two-step administration.
• Long shelf life.
• Environmental durability.
• Packaging and logistics compatibility.
• Validated autoinjector performance.
• Domestic or approved-source manufacturing.

Civilian preparedness

Civilian demand comes from hazardous-materials teams, emergency medical services, law-enforcement agencies, industrial sites and regional stockpiles. This segment is more price-sensitive and usually purchases through centralized public tenders or group procurement arrangements.

Geopolitical events

Chemical attacks, military conflicts, terrorism alerts and heightened public-health preparedness can accelerate procurement. The effect is usually indirect. These events increase inventory targets and shorten purchasing cycles, but they do not create sustained prescription demand.

What is the financial trajectory for pralidoxime chloride autoinjectors?

The financial trajectory is structurally uneven. Revenue generally follows a contract-driven pattern:

Phase	Financial effect
Baseline readiness	Low but recurring maintenance and replacement demand
Procurement award	Large revenue increase concentrated in one or several periods
Delivery period	Manufacturing utilization and working-capital requirements rise
Stockpile saturation	Orders decline after inventory targets are met
Expiry replacement	Demand reappears in scheduled cycles
Emergency event	Potential unplanned acceleration, subject to government authorization

Manufacturers can earn attractive unit economics on specialized autoinjectors because the product requires device assembly, combination-product controls, specialized packaging and validated supply chains. Gross margins can be pressured by low production volumes, expiration-related inventory, quality systems and the need to maintain capacity between contracts.

Public financial filings generally aggregate these sales into broader pharmaceutical, medical-countermeasure or government-contracting categories. A standalone revenue series for pralidoxime chloride autoinjectors is not publicly reported by Pfizer or Meridian Medical Technologies. Financial analysis therefore depends on contract announcements, federal procurement records, production updates and broader government-healthcare disclosures rather than a separately reported product income statement.

How does pralidoxime compare with competing antidote products?

Attribute	Pralidoxime autoinjector	Pralidoxime vial	Atropine autoinjector alone
Field speed	High	Lower	High
Training requirement	Lower	Higher	Lower
Neuromuscular treatment	Yes	Yes	No
Manufacturing complexity	High	Moderate	High
Institutional flexibility	Moderate	High	Moderate
Stockpile suitability	High	Moderate	High
Main use environment	Military and emergency response	Hospitals and clinical settings	Initial emergency treatment

The autoinjector’s main commercial advantage is operational. Its main disadvantage is cost and manufacturing complexity. Vial presentations are more flexible for hospitals and may be less expensive per milligram, but they are less suited to immediate field administration.

What is the regulatory status of pralidoxime autoinjectors?

Pralidoxime autoinjectors are FDA-regulated prescription drug-device combination products. Their commercial requirements include:

• FDA-approved labeling for the drug combination.
• Drug and device manufacturing controls.
• Autoinjector performance validation.
• Human-factors and usability considerations.
• Container-closure and stability data.
• Shelf-life testing.
• Combination-product quality systems.
• Manufacturing-site compliance.

DuoDote and ATNAA are regulated as approved drug products rather than unapproved emergency devices. The FDA labeling identifies organophosphorus nerve-agent and organophosphate poisoning as the relevant use setting.[4][5]

The regulatory barrier is higher than for ordinary pralidoxime injection because a new entrant must qualify both the formulation and the delivery system. A competitor would need to demonstrate reliable dose delivery under emergency-use conditions, including storage and handling requirements.

What is the Orange Book and patent status?

Pralidoxime chloride is an old active pharmaceutical ingredient. Core composition-of-matter protection has expired, and the molecule itself does not provide meaningful exclusivity.

The principal protection issues are therefore:

Protection category	Commercial relevance
Active ingredient patent	Low; historic protection has expired
Combination formulation	Potentially limited
Autoinjector design	More relevant than molecule patents
Manufacturing process	Relevant where process know-how is difficult to reproduce
Trade secrets	Important for device assembly and quality control
Regulatory exclusivity	Generally limited for an established product
Government qualification	High practical importance

An Orange Book listing, if present for a specific approved product, would not necessarily capture all commercially important barriers. Device architecture, injector tolerances, assembly methods, packaging and contract qualification may remain outside conventional pharmaceutical patent analysis.

The principal competitive moat is operational rather than chemical. A supplier with established federal qualification, validated production and a reliable delivery record can be difficult to displace even when the active ingredient is generic.

Are Paragraph IV challenges or generic launches likely?

Paragraph IV litigation risk is limited compared with conventional blockbuster drugs. The key reasons are the small market, limited retail economics and the difficulty of commercializing a compliant autoinjector at sufficient volume.

Generic entry could occur through several routes:

1. A vial-based abbreviated new drug application.
2. A combination autoinjector application.
3. A 505(b)(2) application using established atropine and pralidoxime data.
4. A government-specific procurement product.
5. A device-led product with a new drug application or combination-product pathway.

A vial generic is more likely than a competing branded autoinjector because it requires less device investment. A true autoinjector competitor must solve manufacturing scale, device reliability, human-factors validation, federal qualification and inventory economics.

No major public Paragraph IV dispute is a central market driver for the U.S. pralidoxime autoinjector segment. The absence of blockbuster-level litigation reflects the market’s limited commercial size rather than a lack of technical barriers.

What manufacturing and intellectual-property barriers affect competition?

Manufacturing access is a significant barrier. The product requires coordinated control of:

• Drug formulation and fill-finish operations.
• Autoinjector component sourcing.
• Dose-volume accuracy.
• Mechanical actuation.
• Sterility and container integrity.
• Stability during long-term storage.
• Packaging and labeling for emergency deployment.
• Lot release and government acceptance testing.

Government buyers also value continuity of supply. A new entrant may face qualification delays even if its product has an acceptable price. Contracting agencies often prefer suppliers with proven capacity because stockout risk has national-security implications.

The most defensible assets are likely to be manufacturing know-how, validated device systems, regulatory history and procurement relationships. These factors can support pricing above commodity injectable levels.

Which companies are competing in the market?

The competitive field is narrow:

• Meridian Medical Technologies and Pfizer are associated with major U.S. autoinjector products.
• Generic injectable manufacturers compete in the vial segment.
• Contract manufacturers may participate in device assembly, fill-finish or government supply.
• International suppliers compete through national military and public-health tenders.

Competition is not measured only by product count. It is measured by approved product status, government eligibility, manufacturing redundancy, shelf-life performance and the ability to deliver during a surge.

What generic-entry risks exist?

The most credible generic-entry scenario is gradual substitution in institutional vial demand. Autoinjector substitution is less likely to be rapid because buyers must validate new devices and integrate them into emergency protocols.

Risk	Assessment
Commodity API competition	High
Hospital vial substitution	Moderate to high
Direct autoinjector substitution	Moderate
Sudden price erosion	Low to moderate
Government contract displacement	Moderate
Supply disruption	Material
Patent-based launch blockage	Low

A low-patent environment can increase long-term competition, but the small market may discourage entry. The incumbent’s advantage is strongest when government orders are large, time-sensitive and tied to established product specifications.

What is the investment and commercial outlook?

The commercial outlook is stable but lumpy rather than high-growth. Expected characteristics include:

• Low routine prescription volume.
• High dependence on public-sector contracts.
• Periodic revenue spikes from stockpile replenishment.
• Limited pricing transparency.
• Meaningful working-capital exposure.
• Strong sensitivity to government budgets and preparedness policy.
• Low probability of blockbuster-style expansion.
• Resilience during heightened chemical-threat preparedness.

Revenue upside depends more on contract wins, inventory replacement and international procurement than on patient growth. Margin performance depends on production scale and contract utilization. A supplier with underused capacity may experience weak profitability despite high unit prices.

Key Takeaways

• Pralidoxime chloride autoinjectors are specialized chemical-threat antidotes, not conventional retail pharmaceuticals.
• DuoDote and ATNAA are the main U.S. autoinjector reference products.
• The market is driven by military procurement, government stockpiles and first-responder preparedness.
• Revenue is episodic and contract-based, with no publicly reported standalone product revenue.
• Core pralidoxime composition patents are expired; practical barriers center on devices, manufacturing, regulatory qualification and government contracting.
• Generic vial competition is more credible than immediate direct autoinjector competition.
• The segment has strategic importance but limited secular growth and high revenue variability.

FAQs

Does pralidoxime chloride autoinjector have biosimilar risk?

No. Pralidoxime chloride is a small-molecule drug, so biosimilar regulation does not apply. Competition would arise through generic, 505(b)(2) or combination-product pathways.

Is pralidoxime chloride available without atropine?

Yes. Pralidoxime chloride is available in injectable presentations without atropine, particularly for hospital and institutional use. Autoinjector products generally combine pralidoxime with atropine for emergency administration.

Does the FDA approve pralidoxime for routine pesticide poisoning?

FDA labeling covers organophosphorus nerve-agent and organophosphate poisoning. Clinical use in pesticide poisoning depends on the circumstances, labeling, medical judgment and applicable treatment protocols.

Why are pralidoxime autoinjectors expensive compared with vials?

The autoinjector includes a calibrated delivery mechanism, combination-product controls, specialized packaging, stability requirements and lower production volumes. These costs are not present to the same extent in conventional vial products.

Can a new manufacturer enter the U.S. pralidoxime autoinjector market?

Yes, but entry requires FDA approval, device validation, manufacturing capacity, shelf-life data and access to government procurement channels. The regulatory pathway is feasible, while commercial scale and contract access are the larger constraints.

References

1. Centers for Disease Control and Prevention. (2024). Chemical emergencies: Nerve agents. U.S. Department of Health and Human Services.
2. Administration for Strategic Preparedness and Response. (2024). Strategic National Stockpile. U.S. Department of Health and Human Services.
3. U.S. Department of Defense. (2024). Chemical, biological, radiological and nuclear medical countermeasures.
4. U.S. Food and Drug Administration. (2023). DuoDote prescribing information.
5. U.S. Food and Drug Administration. (2023). ATNAA prescribing information.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.